Takeda Pharmaceutical Company Limited (TAK) Stock Analysis & Winston Score

Takeda Pharmaceutical is a large Japanese drug company that discovers, makes, and sells prescription medicines to patients around the world. Its main focus areas include rare diseases, cancer, digestive disorders, and neuroscience, with key drugs like Entyvio (for bowel disease) and a growing rare disease portfolio. Takeda is one of the largest pharmaceutical companies in Asia and ranks among the top 15 globally by revenue. The company earns money by selling branded prescription drugs to hospitals, clinics, and pharmacies, primarily in the United States, Europe, and Japan. Takeda's competitive position rests on its specialized drug portfolio and a significant research pipeline, though it carries a heavy debt load from its $62 billion acquisition of Shire in 2019. The biggest risk facing Takeda is patent expiration on Entyvio, its top-selling drug, which faces biosimilar competition in the coming years and currently accounts for a large share of revenue.